Viral Hepatitis

You have full text access to this OnlineOpen article

Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C†

  1. Yasuji Arase‡,*,
  2. Fumitaka Suzuki,
  3. Yoshiyuki Suzuki,
  4. Norio Akuta,
  5. Masahiro Kobayashi,
  6. Yusuke Kawamura,
  7. Hiromi Yatsuji,
  8. Hitomi Sezaki,
  9. Tetsuya Hosaka,
  10. Miharu Hirakawa,
  11. Kenji Ikeda,
  12. Hiromitsu Kumada

Article first published online: 24 OCT 2008

DOI: 10.1002/hep.22703

Issue

Hepatology

Hepatology

Volume 49, Issue 3, pages 739–744, March 2009

Additional Information

How to Cite

Arase, Y., Suzuki, F., Suzuki, Y., Akuta, N., Kobayashi, M., Kawamura, Y., Yatsuji, H., Sezaki, H., Hosaka, T., Hirakawa, M., Ikeda, K. and Kumada, H. (2009), Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology, 49: 739–744. doi: 10.1002/hep.22703

Author Information

  1. Department of Hepatology, Toranomon Hospital, Tokyo, Japan

  1. ‡

    fax: (81)-3-3582-7068.

*Department of Hepatology, Toranomon Hospital, 2-2-2, Toranomon, Minato-ku, Tokyo 105-8470, Japan

  1. †

    Potential conflict of interest: Nothing to report.

Publication History

  1. Issue published online: 24 FEB 2009
  2. Article first published online: 24 OCT 2008
  3. Accepted manuscript online: 24 OCT 2008 12:00AM EST
  4. Manuscript Accepted: 13 OCT 2008
  5. Manuscript Received: 25 SEP 2008

Funded by

  • Okinaka Memorial Institute for Medical Research
  • Japanese Ministry of Health, Labor, and Welfare

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (382K)

References

  • 1
    Kiyosawa K, Furuta S. Review of hepatitis C in Japan. J Gastroenterol Hepatol 1991; 6: 383–391.
    Direct Link:
  • 2
    Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, et al. The natural history of community acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1899–1905.
  • 3
    van Rossum TG, Vulto AG, de Man RA, Brouwer JT, Schalm SW. Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther 1998; 12: 199–205.
    Direct Link:
  • 4
    Colombo M, Kuo G, Choo QL, Donato MF, Del Ninno E, Tommasini MA, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989; 2: 1006–1008.
  • 5
    Hasan F, Jeffers LJ, De Medina M, Reddy KR, Parker T, Schiff ER, et al. Hepatitis C-associated hepatocellular carcinoma. HEPATOLOGY 1990; 12: 589–591.
    Direct Link:
  • 6
    Kew MC, Houghton M, Choo QL, Kuo G. Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma. Lancet 1990; 335: 873–874.
  • 7
    Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797–1801.
  • 8
    Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. HEPATOLOGY 1993; 18: 47–53.
    Direct Link:
  • 9
    Gumber SC, Chopra S. Hepatitis C: a multifaceted disease- review of extrahepatic manifestations. Ann Intern Med 1995; 123: 615–620.
  • 10
    Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328: 465–470.
  • 11
    Pawlotsky JM, Roudot-Thoraval F, Simmonds P, Mellor J, Ben Yahia MB, André C, et al. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med 1995; 122: 169–173.
  • 12
    Boadas J, Rodriguez-Espinosa J, Enriquez J, Miralles F, Martínez-Cerezo FJ, González P, et al. Prevalence of thyroid autoantibodies is not increased in blood donors with hepatitis C virus infection. J Hepatol 1995; 22: 611–615.
  • 13
    Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 1490–1495.
  • 14
    Imazeki F, Yokosuka O, Fukai K, Kanda T, Kojima H, Saisho H. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients. Liver Int 2008; 28: 355–362.
    Direct Link:
  • 15
    Arao M, Murase K, Kusakabe A, Yoshioka K, Fukuzawa Y, Ishikawa T, et al. Prevalence of diabetes mellitus in Japanese patients infected chronically with hepatitis C virus. J Gastroenterol 2003; 38: 355–360.
  • 16
    Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160–3167.
  • 17
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Sheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. HEPATOLOGY 1994; 19: 1513–1520.
    Direct Link:
  • 18
    Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. Control Clin Trials 1984; 5: 348–361.
  • 19
    Fabris P, Betterle C, Greggio NA, Zanchetta R, Bosi E, Biasin MR, et al. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1998; 28: 514–517.
  • 20
    di Cesare E, Previti M, Russo F, Brancatelli S, Ingemi MC, Scoglio R, et al. Interferon-alpha therapy may induce insulin autoantibody development in patients with chronic viral hepatitis. Dig Dis Sci 1996; 41: 1672–1677.
  • 21
    Fajans S. Classification and diagnosis of diabetes. In: Rifkin H, Porte D, eds. Diabetes Mellitus: Theory and Practice. 4th ed. New York: Elsevier, 1990: 346–356.
  • 22
    Simó R, Lecube A, Genescà J, Esteban JI, Hernández C. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care 2006; 29: 2462–2466.
  • 23
    Romero-Gómez M, Fernández-Rodríguez CM, Andrade RJ, Diago M, Alonso S, Planas R, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008; 48: 721–727.
  • 24
    Romero-Gómez M. Insulin resistance and hepatitis C. World J Gastroenterol 2006; 12: 7075–7080.
  • 25
    Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840–848.
  • 26
    Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636–641.
  • 27
    Waki K, Noda M, Sasaki S, Matsumura Y, Takahashi Y, Isogawa A, et al. Alcohol consumption and other risk factors for self-reported diabetes among middle-aged Japanese: a population-based prospective study in the JPHC study cohort I. Diabet Med 2005; 22: 323–331.
    Direct Link:
  • 28
    Thuluvath PJ, John PR. Association between hepatitis C, diabetes mellitus, and race. a case-control study. Am J Gastroenterol 2003; 98: 438–441.
  • 29
    Mehta SH, Brancati FL, Strathdee SA, Pankow JS, Netski D, Coresh J, et al. Hepatitis C virus infection and incident type 2 diabetes. HEPATOLOGY 2003; 38: 50–56.
    Direct Link:
  • 30
    Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047–1053.
  • 31
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853.
  • 32
    UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–865.
  • 33
    Elbein SC. The search for genes for type 2 diabetes in the post-genome era. Endocrinology 2002; 143: 2012–2018.
  • 34
    Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. HEPATOLOGY 2008; 47: 1856–1862.
    Direct Link:
View Full Article (HTML) Get PDF (382K)